SCHEMBL6049203

SCHEMBL6049203

CS(=O)(=O)Nc1ccc(Oc2ccc(OC(F)(F)F)cc2)c(C2CCCN2)c1

nearest known ligand 0.48

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 1/20 0.48
▸ SLC6A4 P31645 4/20 0.43
▸ SLC6A2 P23975 2/20 0.43
▸ SLC6A3 Q01959 2/20 0.43
▸ HTR6 P50406 1/20 0.43
▸ EPHX2 P34913 2/20 0.40
▸ NR1H4 Q96RI1 1/20 0.40
▸ ABL1 P00519 6/20 0.40
▸ BCR P11274 1/20 0.40
▸ IDH1 O75874 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ BRD4 O60885 2/20 0.39
▸ HTR2C P28335 1/20 0.38
▸ DPP4 P27487 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7522746 0.99 KIF11 (0.47) KIF11SLC6A4SLC6A2SLC6A3HTR6
Hydrochloric Acid SCHEMBL6049206 0.89 PTPN1 (0.43) KIF11SLC6A4SLC6A2SLC6A3HTR6
SCHEMBL6049201 0.81 TACR1 (0.40) SLC6A4SLC6A2SLC6A3HTR6ABL1
SCHEMBL6049200 0.77 KIF11 (0.45) KIF11SLC6A4SLC6A2SLC6A3EPHX2
SCHEMBL6049218 0.76 HSPB1 (0.41) MEN1KMT2AHTR2C
SCHEMBL6049224 0.75 KIF11 (0.60) KIF11SLC6A4SLC6A2SLC6A3EPHX2
SCHEMBL3107843 0.72 KIF11 (0.82) KIF11EPHX2NR1H4ABL1BCR
SCHEMBL6049238 0.69 PPARG (0.52) KIF11SLC6A4SLC6A2SLC6A3EPHX2
SCHEMBL21009692 0.68 MEN1 (0.48) KIF11SLC6A4SLC6A3MEN1KMT2A
SCHEMBL7170392 0.67 EPHX2 (0.42) EPHX2KMT2ABRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1184372-B1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) PFIZER LTD (GB) 2006-04-26 — — EP claimed
US-6630504-B2 Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, sexual dysfunction PFIZER INC. 2003-10-07 — — US claimed
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs PFIZER INC. 2002-12-05 — — US claimed
EP-1184372-A1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) Pfizer Limited (GB) 2002-03-06 — — EP claimed
EP-1184372-B1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) PFIZER LTD (GB) 2006-04-26 — — EP disclosed
US-6630504-B2 Activity as selective serotonin re- uptake inhibitors (SSRIs); for therapy and prophylaxis of depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, sexual dysfunction PFIZER INC. 2003-10-07 — — US disclosed
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs PFIZER INC. 2002-12-05 — — US disclosed
EP-1184372-A1 Phenoxyphenylheterocycle derivatives as selective serotonin reuptake inhibitors (SSRIs) Pfizer Limited (GB) 2002-03-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020183303-A1 Phenoxyphenylheterocyclyl derivatives as SSRIs CRHR1, NR3C1, HTR6 KIF11 2354/4885SLC6A4 67/4885SLC6A2 48/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback